Navigation Links
ChemoCentryx Initiates Phase II Clinical Trial for CCX168, a Novel Small Molecule C5aR Antagonist for the Treatment of Vasculitis
Date:10/17/2011

very technologies to the design of small molecule C5aR antagonists and selected CCX168 based on its potency, selectivity and favorable pharmacokinetics. CCX168 is one of four drug candidates discovered and developed by ChemoCentryx under the Company's alliance with GlaxoSmithKline (GSK) to identify molecules targeting four specific chemokine and chemoattractant receptors.  

About ANCA-Associated Vasculitis

Granulomatous polyangiitis and microscopic polyangiitis vasculitides are associated with anti-neutrophil cytoplasmic antibodies (ANCA). These auto-antibodies lead to the activation and increased adhesiveness of neutrophils to endothelial cells that line the blood vessels. These accumulating adhering neutrophils initiate an inflammatory cascade in the small blood vessels by secreting pro-inflammatory cytokines and chemoattractants.

If left untreated, AAV may lead to renal and pulmonary failure and is often fatal. AAV is currently treated with pulses of cyclophosphamide and high-dose systemic corticosteroids. Little advance in the treatment of these diseases has been made since the 1970's when these treatments were first introduced. Cyclophosphamide is a toxic alkylating agent. Systemic corticosteroid use is associated with increased risk of infection, osteoporosis, etc. Rituximab, azathioprine, methotrexate, or mycophenolate mofetil therapy are also used, but these drugs are associated with an increased risk of infection, bone marrow suppression, certain types of cancer, serious and sometimes fatal infusion reactions and progressive multifocal leukoencephalopathy (rituximab). Therefore, there is clearly still a substantial unmet medical need in treatment of patients with AAV.

About ChemoCentryx

ChemoCentryx, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
2. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
3. PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryxs Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
4. ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Maintaining Remission in Patients with Crohns Disease
5. ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases
6. ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference
7. ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis
8. ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohns Disease at the Digestive Disease Week (DDW) 2010 Conference
9. ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD)
10. ChemoCentryx Reports One-Year Results from PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Treating Patients with Crohns Disease at the United European Gastroenterology Federation (UEGW) Meeting
11. ChemoCentryx Reports Positive Phase I Results for CCX168, a Novel C5aR Antagonist, at the Annual American College of Rheumatology Meeting (ACR)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/17/2013)...  As the Share Repurchase Resolution has been passed at ... Corporation, plc (NYSE: ELN ) has lapsed in ... Proceedings referred to below and any consequent decision of the ... to the extent that it would have been had it ... Repurchase Resolution being passed. There can be no assurance as ...
(Date:6/17/2013)... Mass. , and SYDNEY ... Inc. (Nasdaq: HTWR ; ASX: HIN), ... support technologies that are revolutionizing the treatment of ... Food and Drug Administration (FDA) has granted conditional ... that allows HeartWare to commence enrollment in an ...
(Date:6/17/2013)... Perrigo Company (NYSE: PRGO ; ... agreement to acquire and has completed the acquisition of ... Fera Pharmaceuticals, LLC and its affiliates (Fera), a privately-held, ... pharmaceutical company. The acquired portfolio, including nine prescription ANDA ... during calendar year 2012. Terms of the transaction include ...
Breaking Medicine Technology:Royalty Pharma Informs Elan Stockholders About The Consequences Arising From The Results Of The Elan EGM Earlier Today 2Royalty Pharma Informs Elan Stockholders About The Consequences Arising From The Results Of The Elan EGM Earlier Today 3Royalty Pharma Informs Elan Stockholders About The Consequences Arising From The Results Of The Elan EGM Earlier Today 4Royalty Pharma Informs Elan Stockholders About The Consequences Arising From The Results Of The Elan EGM Earlier Today 5Royalty Pharma Informs Elan Stockholders About The Consequences Arising From The Results Of The Elan EGM Earlier Today 6Royalty Pharma Informs Elan Stockholders About The Consequences Arising From The Results Of The Elan EGM Earlier Today 7Royalty Pharma Informs Elan Stockholders About The Consequences Arising From The Results Of The Elan EGM Earlier Today 8Royalty Pharma Informs Elan Stockholders About The Consequences Arising From The Results Of The Elan EGM Earlier Today 9Royalty Pharma Informs Elan Stockholders About The Consequences Arising From The Results Of The Elan EGM Earlier Today 10HeartWare Receives Conditional Approval From FDA to Enroll Supplemental Patient Cohort in Destination Therapy Trial 2HeartWare Receives Conditional Approval From FDA to Enroll Supplemental Patient Cohort in Destination Therapy Trial 3HeartWare Receives Conditional Approval From FDA to Enroll Supplemental Patient Cohort in Destination Therapy Trial 4Perrigo Company Acquires Ophthalmic Product Portfolio From Fera Pharmaceuticals, LLC For An Upfront Payment Of $93 Million 2Perrigo Company Acquires Ophthalmic Product Portfolio From Fera Pharmaceuticals, LLC For An Upfront Payment Of $93 Million 3
... MINNEAPOLIS, Sept. 29 ProUroCare Medical Inc. (OTC Bulletin ... imaging products, today announced the signing of an agreement ... LP of Juno Beach, Fla.  The proceeds of the ... portfolio and to support scale-up activities associated with final ...
... PROSPECT, Ill., Sept. 29 Earlier this year, the National ... was introduced to the AWARxE campaign, which was created and ... the power of the campaign, NABP obtained the AWARxE program ... level. The Foundation was inspired to create ...
Cached Medicine Technology:UPDATE - ProUroCare Announces $3 Million Financing Agreement 2UPDATE - ProUroCare Announces $3 Million Financing Agreement 3NABP Purchases AWARxE Consumer Protection Program 2
(Date:6/17/2013)... (PRWEB) June 17, 2013 The producers ... a new series of reports highlighting how sustainable farming ... of growing populations and their demand on food supplies. ... independently produced television series airing in markets around the ... the legendary Martin Sheen, who is marking the start ...
(Date:6/17/2013)... 2013 As da Vinci robot lawsuit ... country, Bernstein Liebhard LLP notes that a recent report ... of the disturbing robotic surgery complications alleged to have been ... things, the June 14th broadcast revealed that the U.S. Food ... of da Vinci patients who suffered burns, cuts and infections ...
(Date:6/17/2013)... MelanSol® All Natural Skin Care now ... US distributor for MelanSol®, has partnered with the Central ... Bank to support their efforts to feed hungry ... they receive a portion of every sale of ... Contributions will be given on sales from http://www.PureSunscreen.com ...
(Date:6/17/2013)... The Professional Center for Enhanced Performance ... open in Schertz. The center will offer ... to educational support groups. , Neurofeedback treatment is ... with athletic performance, post traumatic stress disorder, and ... LCSW, works primarily with those affected by military ...
(Date:6/17/2013)... Cleveland, Ohio (PRWEB) June 17, 2013 ... nerve damage in his legs, proved that there are ... Cleveland Marathon. While he didn’t place in the ... Volkswagen Cup. The esteemed award recognizes the individual ... event. Emerson was able to raise more than ...
Breaking Medicine News(10 mins):Health News:Da Vinci Robot Lawsuit News: Bernstein Liebhard LLP Comments on NBC Report Detailing Robotic Surgery Complications 2Health News:Da Vinci Robot Lawsuit News: Bernstein Liebhard LLP Comments on NBC Report Detailing Robotic Surgery Complications 3Health News:All Natural Sunscreen Fights Hunger 2Health News:Professional Center for Enhanced Performance Opens in Schertz 2Health News:Cancer Survivor David Emerson Awarded Volkswagen Cup at Cleveland Marathon 2
... Cover the Uninsured Network formed to raise awareness and advocate ... ... non-partisan effort., DETROIT, March 3 Leaders from ... community have signed on as supporters of the newly formed,Michigan Cover ...
... MEMPHIS, Tenn., March 3 Smith & Nephew,Inc.,s ... business today,announced Japanese regulatory approval of its award ... is the only orthopaedic company to offer such ... is a,proprietary transformed metal alloy with a ceramic ...
... OrthoSynetics(TM), the largest,provider of business services to orthodontic ... Director, IT Infrastructure., "Hiring Brad is in ... and providing the most innovative technology to,our doctors ... CEO,OrthoSynetics(TM). "In a very short period of time, ...
... BALTIMORE, Md., March 3 Super Bowl champ ... lateral sclerosis (ALS),by top doctors at The Robert ... spearheading a spring footrace organized by the Center ... syndrome commonly known as "Lou Gehrig,s,Disease.", (Photo: ...
... relax the gut and help accommodate a big meal ... The proteins could offer a future drug target against ... In a paper published in this months issue of ... King and Dr Andrea Townsend-Nicholson explored the molecular basis ...
... spread by oil spills, forest fires and car exhaust ... a second way in which smoking delays bone healing, ... of the Orthopaedic Research Society in San Francisco. , ... Medical Center identified one ingredient in smoke, nicotine, that ...
Cached Medicine News:Health News:Michigan Leaders Join Network to Push for Coverage of State's 1.4 Million Uninsured 2Health News:Smith & Nephew Wins OXINIUM(TM) Approval in Japan 2Health News:Smith & Nephew Wins OXINIUM(TM) Approval in Japan 3Health News:Brad Williams Joins OrthoSynetics(TM) as Director, IT Infrastructure 2Health News:O.J. Brigance Named Honorary Chair of May 3 Race to Cure ALS, Confirms His Diagnosis by The Robert Packard Center for ALS Research at Johns Hopkins 2Health News:Tighter tummies: A new way to combat weight gain 2Health News:Toxins in cigarette smoke prevent stem cells from becoming cartilage 2Health News:Toxins in cigarette smoke prevent stem cells from becoming cartilage 3
The Solar Radius Chair is a multi-functional and cost effective working environment. It can be used for simple and advanced urodynamic studies as well as for routine gynecology investigations....
... The Sonesta 6202 is the ... with our most popular accessories, ... for a myriad of exam ... (yet quiet) motors allow fast ...
... Model BR2 Bilirubin STAT-Analyzer® provides a rapid, ... in neonates. And because it's so compact ... for virtually any laboratory. The Model BR2 ... the only instrument that measures total and ...
... The Advanced® 2020 Multi-Sample Osmometer provides ... industrial, and research settings. These results ... freezing-point method, which determines total concentration. ... on-board data management, automated sample handling, ...
Medicine Products: